Last reviewed · How we verify

NCT06116370

The Clinical Efficacy of Rezūm Therapy Versus Bipolar Trans-urethral Resection of the Prostate for Treatment Benign Prostatic Hyperplasia

Completed NA Last updated 7 November 2023
What this trial tests

NA trial testing Rezum procedure in Prostatic Hyperplasia in 100 participants. Completed in 1 September 2023.

Timeline
1 June 2021
Primary endpoint
1 June 2023
1 September 2023

Quick facts

Lead sponsorAin Shams University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date1 June 2021
Primary completion1 June 2023
Estimated completion1 September 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 50 to 80, male only, with Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We aimed to compare the efficacy and safety of Rezūm therapy and bipolar transurethral resection of prostate (B-TURP) for the management of benign prostatic hyperplasia (BPH) of 50-120gm size.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Prostatic Hyperplasia

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06116370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing